What Enanta Pharmaceuticals, Inc. told the SEC could break it.

Enanta is almost entirely dependent on one collaborator: since August 2017 substantially all of its royalty revenue has come from AbbVie's net sales of the MAVYRET/MAVIRET HCV regimen (annually tiered double-digit royalties on 50% of net sales), and that revenue is falling as AbbVie's reported HCV sales decline and faces competition from Gilead; future royalties depend on AbbVie's HCV market share, pricing and patient volumes, so erosion of the AbbVie relationship or HCV market would sharply reduce Enanta's revenue.

“Since August 2017, substantially all of our royalty revenue has been derived from AbbVie's net sales of MAVYRET/MAVIRET.”

Enanta relies on third parties located in China to manufacture and supply certain key intermediates used to make the active pharmaceutical ingredients (API) for its product candidates, and a significant disruption of those Chinese researchers/manufacturers — from a trade war, geopolitical unrest, legislation such as the proposed BIOSECURE Act, sanctions, other regulatory requirements or an epidemic — could materially and adversely affect its business, with currency/wage inflation in China also raising costs.

“we have relied on third parties located in China to manufacture and supply certain key intermediates used in the manufacture of our active pharmaceutical ingredients, or API, for our current product candidates, and we expect to continue to use such third-party manufacturers for such intermediates for any product candidates we deve”

Enanta's internal product candidates are only in Phase 1 or Phase 2 clinical development and are not expected to generate product-sales revenue for at least several years, so the company depends on its declining AbbVie HCV royalty stream and its cash reserves to fund R&D; it has also monetized royalties to OMERS (capped at 1.42x OMERS' purchase price), and continued clinical-stage cash burn against a falling royalty base creates funding and execution risk.

“As our internal product candidates are currently in Phase 1 or Phase 2 clinical development, we have not generated any revenue from our own product sales. We do not expect to generate any revenue from product sales derived from these product candidates for at least the next several years.”

Enanta's royalty stream and future products are exposed to drug-pricing regulation: U.S. federal/state Most Favored Nation (MFN) pricing models tie reimbursement to the lowest prices paid abroad, foreign governments (especially in the EU and Japan) impose strict price controls and reimbursement negotiations, and U.S. programs require Medicaid rebates and Part D coverage-gap discounts and manufacturer fees; its internal pipeline also depends on uncertain FDA and foreign regulatory approvals.

“federal and state governments have proposed or implemented Most Favored Nation, or MFN, pricing models that tie reimbursement rates for certain drugs to the lowest prices paid by other countries.”